Physician profile
Alyssa Murata
NPI 1811344864
$1,269.24
in general payments reported to CMS, 2019-2025
19 companies · $475 in 2025
The $475 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.96 · 2022: $61.06 · 2023: $274 · 2024: $437 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $281.42 | 2023-2025 | Azstarys |
| Cranial Technologies, INC | $200.15 | 2022-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $120.88 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $118.93 | 2023-2025 | Dyanavel Xr |
| Pfizer INC. | $94.13 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $93.63 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $77.28 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $38.94 | 2023 | |
| Glaxosmithkline, LLC. | $36.08 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.22 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $31.33 | 2023-2024 | Varivax, Vaxneuvance, M-M-R II |
| Biomarin Pharmaceutical INC. | $26.00 | 2025 | Voxzogo 1.2mg |
| Verrica Pharmaceuticals INC. | $19.83 | 2024 | Ycanth |
| Ironwood Pharmaceuticals, INC | $18.22 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $17.77 | 2025 | Neffy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $16.86 | 2023 | Methylphenidate Hydrochloride |
| Aytu Biopharma, INC. | $16.20 | 2024 | Karbinal |
| Kaleo, INC. | $13.31 | 2023 | Auvi-Q |
| Sobi, INC | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Murata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.